Welcome to our dedicated page for Regen Biopharma SEC filings (Ticker: RGBPP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Regen BioPharma PFD A (RGBPP) SEC filings page aggregates regulatory documents for Regen BioPharma, Inc., a Nevada‑incorporated biotechnology company trading on the OTC Pink marketplace under RGBP and RGBPP. These filings provide detailed insight into the company’s capital structure, financing activities, and progress as it develops immunology and immunotherapy programs such as HemaXellerate.
Regen BioPharma’s recent Form 8‑K reports describe unregistered sales of equity securities, including Tier 2 Regulation A offerings and issuances under Section 4(a)(2) of the Securities Act of 1933. The filings specify the number of common shares issued, the cash consideration received, and instances where shares were issued to satisfy principal and accrued interest on convertible indebtedness. They also note that certain proceeds are allocated to working capital and that shares are sold directly through company management without underwriters or commissions.
Through this page, users can access Regen BioPharma’s SEC submissions associated with both its common and preferred equity, including RGBPP. Filings such as 8‑K, and, where available, periodic reports like 10‑K and 10‑Q, outline key information on the company’s financial condition, risk factors, and business description, including its focus on cell therapies, RNA vaccines, RNA and DNA therapeutics, and small molecule drugs for cancer and autoimmune disorders.
Stock Titan enhances these documents with AI‑powered summaries that highlight the most important points in lengthy filings, helping readers quickly understand items such as new share issuances, changes in capital structure, and material events. Real‑time updates from the SEC’s EDGAR system ensure that new Regen BioPharma filings appear promptly, while dedicated views for insider‑related forms like Form 4, and for annual and quarterly reports, allow investors to review trading by company insiders, compensation disclosures, and detailed financial and operational data with simplified explanations.
Regen BioPharma, Inc. issued 77,849,847 common shares between February 4 and February 27, 2026 to settle outstanding obligations. The shares were issued to satisfy
The issuance was conducted as an unregistered private placement under Section 4(a)(2) of the Securities Act of 1933, with no underwriters, commissions or general solicitation, and shares were sold directly through management. As of
Regen BioPharma, Inc. reported another heavy loss for the quarter ended December 31, 2025, while remaining in an early-stage development phase with no approved products. Net revenue was modest at $59,065, unchanged from the prior-year quarter and largely driven by license agreements with Oncology Pharma and related-party Zander Therapeutics.
Operating expenses climbed sharply to $610,689 from $120,443, mainly due to $210,000 in research and development spending and substantially higher general and administrative costs. The company posted an operating loss of $551,624 and a net loss of $967,853, widening from $515,384 a year earlier, while also recording significant derivative expense tied to its convertible notes.
Liquidity remains strained. Cash fell to just $4,578 and total assets were $237,076 against current liabilities of $6,810,073, leaving a stockholders’ deficit of $(6,572,997) and a derivative liability of $2,460,443. Management explicitly notes “significant doubt” about the company’s ability to continue as a going concern and plans to rely on additional equity and debt financing, including recent share issuances, to fund operations and clinical plans.
Regen BioPharma, Inc. reported several unregistered common stock issuances involving debt conversion and a small cash raise. On January 15, 2026 it issued 5,000,000 shares to satisfy
Regen Biopharma, Inc. announced a special stock dividend in the form of its authorized but unissued Series A Preferred Stock. Shareholders of record on February 3, 2026 are scheduled to receive the dividend on or about February 9, 2026.
Each eligible holder will receive one share of Series A Preferred Stock for every one share of Regen Biopharma common stock, Series A Preferred Stock, Series AA Preferred Stock, Series M Preferred Stock, and Series NC Preferred Stock owned as of the record date. The dividend is paid entirely in shares, not cash, and applies across these listed classes of the company’s stock.
Regen Biopharma, Inc. is an early-stage Nevada biotech focused on regenerative medicine and immuno-oncology, with no clinical trials yet started and no conclusions of efficacy for its product candidates. The company is developing several NR2F6‑targeted programs, including HemaXellerate for severe aplastic anemia, dCellVax and tCellVax cell therapies, DiffronC and DuraCar for solid tumors, plus small‑molecule NR2F6 modulators, all in pre‑clinical or IND‑stage development.
Regen controls a portfolio of issued U.S. patents around NR2F6 modulation, cancer vaccines, and gene‑silencing technologies and monetizes some of this IP through licenses, notably to Zander Therapeutics for veterinary uses and to Oncology Pharma for human pancreatic and colon cancer indications, with upfront fees, royalties of 4–5% of Net Sales, and 10% of sublicense consideration. As of December 26, 2025, the company had 108,054,704 common shares outstanding and multiple preferred series, following a 1‑for‑1500 reverse split and a 2024 Series A preferred stock dividend, and continues to fund operations through Regulation A offerings, convertible notes, and share issuances for debt settlement and consulting services.
Regen BioPharma, Inc. filed an 8‑K disclosing unregistered sales of common stock. The company issued 6,800,000 shares on October 8, 2025 for $68,000 under a Tier 2 Regulation A offering sold directly by management.
On October 27, 2025, it issued 3,500,000 shares for $35,000 via Tier 2 Regulation A, and separately issued 4,500,000 shares to satisfy $30,204 of principal and $13,536 of accrued interest on convertible indebtedness under Section 4(a)(2), with no underwriters, commissions, or general solicitation.
On October 28, 2025, Regen issued 7,100,000 shares for $71,000 via Tier 2 Regulation A, and on November 10, 2025, it issued 1,780,000 shares for $17,800 via Tier 2 Regulation A. All Tier 2 Regulation A sales were conducted directly through management.
Regen BioPharma, Inc. disclosed that it raised cash through several unregistered sales of common stock to unaffiliated investors in mid-September
The shares were issued in reliance on Regulation A exemptions from registration under the Securities Act of 1933. No underwriters were involved, the sales were conducted directly by management without commissions or other consideration paid, and the company states that proceeds from each sale will be used for working capital.
Quick Capital, LLC reported beneficial ownership of 3,320,000 shares of Regen BioPharma, Inc. common stock, representing 9.9% of the outstanding class. The filing states Quick Capital has sole voting and sole dispositive power over all shares reported and identifies the filer as a Wyoming LLC with its business address in Miami, FL.
The statement is a passive Schedule 13G disclosure certifying the shares were not acquired to change or influence control of the issuer. No group affiliations, subsidiaries, or holdings on behalf of others are reported, and no shared voting or dispositive powers are disclosed.